Azetukalner (XEN1101)

Name: Azetukalner (XEN1101) in Focal onset seizures: American hospital formulary service (AHFS), or other drug classification
Published: 2026-09-21T21:41:53-04:00

Focal onset seizures

Manufacturer: Xenon Pharmaceuticals
Regulatory submission: NDA submitted September 2026
Launch: Not announced
Last updated: September 21, 2026

Section

Product information and disease description Product description Product information

American hospital formulary service (AHFS), or other drug classification

1 evidence topic · 2 sources

Mechanistic classification

“On the basis of these data, azetulkalner can be classified as a selective opener of neuronal Kv7.2/7.3 channels, with no effects on cardiac (Kv7.1) channels.” (opens the source at this quote in a new tab)

AHFS classification

No evidence found.